Zacks Research Analysts Lower Earnings Estimates for A

Agilent Technologies, Inc. (NYSE:A) – Investment analysts at Zacks Research decreased their Q2 2025 EPS estimates for shares of Agilent Technologies in a report issued on Wednesday, March 19th. Zacks Research analyst R. Department now anticipates that the medical research company will earn $1.26 per share for the quarter, down from their previous forecast of $1.33. The consensus estimate for Agilent Technologies’ current full-year earnings is $5.57 per share. Zacks Research also issued estimates for Agilent Technologies’ Q4 2025 earnings at $1.58 EPS, Q3 2026 earnings at $1.53 EPS, Q4 2026 earnings at $1.65 EPS, FY2026 earnings at $6.03 EPS, Q1 2027 earnings at $1.61 EPS and FY2027 earnings at $6.61 EPS.

Agilent Technologies (NYSE:A) last released its quarterly earnings data on Wednesday, February 26th. The medical research company reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.27 by $0.04. The company had revenue of $1.68 billion during the quarter, compared to analyst estimates of $1.67 billion. Agilent Technologies had a net margin of 19.27% and a return on equity of 25.56%.

Other equities analysts have also recently issued research reports about the company. Bank of America decreased their price target on Agilent Technologies from $153.00 to $150.00 and set a “neutral” rating for the company in a report on Friday, December 13th. StockNews.com upgraded shares of Agilent Technologies from a “hold” rating to a “buy” rating in a research note on Tuesday, December 24th. Wells Fargo & Company lowered their price target on shares of Agilent Technologies from $157.00 to $155.00 and set an “overweight” rating for the company in a report on Monday, December 9th. Sanford C. Bernstein cut their price objective on shares of Agilent Technologies from $140.00 to $135.00 and set a “market perform” rating on the stock in a report on Tuesday, November 26th. Finally, Robert W. Baird lowered their target price on Agilent Technologies from $161.00 to $159.00 and set an “outperform” rating for the company in a research note on Thursday, February 27th. Seven analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $146.15.

Agilent Technologies Price Performance

A stock opened at $120.72 on Friday. The firm has a market cap of $34.42 billion, a P/E ratio of 27.75, a price-to-earnings-growth ratio of 3.43 and a beta of 1.11. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.66 and a current ratio of 2.20. Agilent Technologies has a 1 year low of $117.17 and a 1 year high of $155.35. The stock has a 50-day simple moving average of $136.74 and a 200-day simple moving average of $137.30.

Institutional Trading of Agilent Technologies

Large investors have recently added to or reduced their stakes in the business. CKW Financial Group increased its position in shares of Agilent Technologies by 114.9% during the 4th quarter. CKW Financial Group now owns 187 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 100 shares during the period. Global X Japan Co. Ltd. increased its position in shares of Agilent Technologies by 161.1% during the 4th quarter. Global X Japan Co. Ltd. now owns 188 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 116 shares during the period. Redwood Park Advisors LLC acquired a new position in shares of Agilent Technologies during the 4th quarter valued at $27,000. Lee Danner & Bass Inc. acquired a new position in shares of Agilent Technologies during the 4th quarter valued at $29,000. Finally, Sunbelt Securities Inc. increased its position in shares of Agilent Technologies by 640.0% during the 4th quarter. Sunbelt Securities Inc. now owns 222 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 192 shares during the period.

Insiders Place Their Bets

In other news, CEO Padraig Mcdonnell sold 1,911 shares of the stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $150.00, for a total transaction of $286,650.00. Following the sale, the chief executive officer now directly owns 39,652 shares in the company, valued at approximately $5,947,800. This represents a 4.60 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Rodney Gonsalves sold 1,908 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $121.98, for a total value of $232,737.84. Following the sale, the vice president now owns 21,786 shares in the company, valued at $2,657,456.28. The trade was a 8.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

Agilent Technologies Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 23rd. Shareholders of record on Tuesday, April 1st will be issued a dividend of $0.248 per share. This represents a $0.99 dividend on an annualized basis and a yield of 0.82%. The ex-dividend date is Tuesday, April 1st. Agilent Technologies’s dividend payout ratio is presently 22.76%.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.